Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real‐life combo study
暂无分享,去创建一个
R. Fanin | L. Pagano | M. Caira | A. Nosari | M. Picardi | A. Busca | G. Milone | S. Cesaro | R. Scimé | C. Cattaneo | L. Melillo | A. Candoni | R. Fanci | C. Caramatti | M. Delia | A. Bonini | M. Giacchino
[1] J. Wingard,et al. Combination Antifungal Therapy for Invasive Aspergillosis , 2015, Annals of Internal Medicine.
[2] D. Kontoyiannis,et al. Risk factors for early mortality in haematological malignancy patients with pulmonary mucormycosis , 2014, Mycoses.
[3] Ronald N. Jones,et al. Echinocandin and Triazole Antifungal Susceptibility Profiles for Clinical Opportunistic Yeast and Mold Isolates Collected from 2010 to 2011: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values for Characterization of Geographic and Temporal Trends of Antifungal Resistance , 2013, Journal of Clinical Microbiology.
[4] L. Pagano,et al. Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries , 2013, Haematologica.
[5] M. Sanz,et al. Outcome of Antifungal Combination Therapy for Invasive Mold Infections in Hematological Patients is Independent of the Chosen Combination , 2012, Mediterranean journal of hematology and infectious diseases.
[6] A. Thiébaut,et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3—2009 Update , 2011, Bone Marrow Transplantation.
[7] C. Cordonnier,et al. Impact of invasive fungal disease on the chemotherapy schedule and event-free survival in acute leukemia patients who survived fungal disease: a case-control study , 2011, Haematologica.
[8] N. Kröger,et al. Caspofungin plus posaconazole as salvage therapy of invasive fungal infections in immunocompromised patients , 2011, Mycoses.
[9] I. Raad,et al. Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients? , 2010, Cancer.
[10] C. Romano,et al. Zygomycosis in Italy: A Survey of FIMUA-ECMM (Federazione Italiana Di Micopatologia Umana ed Animale and European Confederation of Medical Mycology) , 2009, Journal of chemotherapy.
[11] Nilo A. Avila,et al. Combination Therapy in Treatment of Experimental Pulmonary Aspergillosis: In Vitro and In Vivo Correlations of the Concentration- and Dose- Dependent Interactions between Anidulafungin and Voriconazole by Bliss Independence Drug Interaction Analysis , 2009, Antimicrobial Agents and Chemotherapy.
[12] J. Sobel,et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] D. Denning,et al. Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis , 2009, Transplant infectious disease : an official journal of the Transplantation Society.
[14] E. Anaissie,et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] C. Junghanss,et al. Treatment of invasive fungal infections in cancer patients—Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) , 2009, Annals of Hematology.
[16] J. Perfect,et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[17] M. Fiegl,et al. A clinical cohort trial of antifungal combination therapy: efficacy and toxicity in haematological cancer patients , 2008, Annals of Hematology.
[18] Raoul Herbrecht,et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[19] B. Spellberg,et al. Combination Echinocandin-Polyene Treatment of Murine Mucormycosis , 2008, Antimicrobial Agents and Chemotherapy.
[20] S. de Botton,et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies , 2007, Cancer.
[21] J. Perfect,et al. Combination antifungal therapy: what can and should we expect? , 2007, Bone Marrow Transplantation.
[22] A. Glasmacher,et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis , 2006, Cancer.
[23] Russell E. Lewis,et al. Decision Making in Antifungal Monotherapy versus Combination Therapy , 2006, Pharmacotherapy.
[24] T. Patterson,et al. Sequential or Combination Antifungal Therapy with Voriconazole and Liposomal Amphotericin B in a Guinea Pig Model of Invasive Aspergillosis , 2006, Antimicrobial Agents and Chemotherapy.
[25] C. McCulloch,et al. Impact of a Piperacillin‐Tazobactam Shortage on Antimicrobial Prescribing and the Rate of Vancomycin‐Resistant Enterococci and Clostridium difficile Infections , 2006, Pharmacotherapy.
[26] Steve A. Hernandez,et al. Caspofungin and Liposomal Amphotericin B Therapy of Experimental Murine Scedosporiosis , 2005, Antimicrobial Agents and Chemotherapy.
[27] D. MacCallum,et al. Efficacy of Caspofungin and Voriconazole Combinations in Experimental Aspergillosis , 2005, Antimicrobial Agents and Chemotherapy.
[28] D. Kontoyiannis,et al. Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis , 2005, Cancer.
[29] J. Powers. Considerations in clinical trials of combination antifungal therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[30] Russell E. Lewis,et al. Toward more effective antifungal therapy: the prospects of combination therapy , 2004, British journal of haematology.
[31] Russell E. Lewis,et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies , 2003, Cancer.
[32] T. Walsh,et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. , 2003, The Journal of infectious diseases.
[33] G. Alangaden,et al. Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus. , 2003, The Journal of antimicrobial chemotherapy.
[34] K. Sepkowitz,et al. Refractory Aspergillus pneumonia in patients with acute leukemia , 2003, Cancer.
[35] J. Rex,et al. In Vitro Synergy of Caspofungin and Amphotericin B against Aspergillus and Fusarium spp , 2002, Antimicrobial Agents and Chemotherapy.
[36] D. Kontoyiannis,et al. Rationale for Combination Antifungal Therapy , 2001, Pharmacotherapy.
[37] Qinying Zhao,et al. Influence of Coadministration of Fluoxetine on Cisapride Pharmacokinetics and QTc Intervals in Healthy Volunteers , 2001, Pharmacotherapy.
[38] D. Alling,et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. , 1979, The New England journal of medicine.
[39] D. Lalloo,et al. Combination antifungal therapy for cryptococcal meningitis. , 2013, The New England journal of medicine.
[40] S. Kravchenko,et al. INVASIVE ASPERGILLOSIS IN PATIENTS WITH ACUTE LEUKEMIA , 2013 .
[41] G. Maschmeyer,et al. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. , 2007, Drugs.
[42] D. Denning,et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[43] H. Bloom,et al. Hematologic Malignancies , 1986, UICC Current Treatment of Cancer.
[44] A RANDOMISED , 2022 .